Tirzepatide

Tirzepatide is a medication that activates both GIP and GLP-1 receptors, which are involved in appetite, fullness, glucose regulation, and other metabolic processes. For appropriate patients, tirzepatide can significantly reduce appetite and support weight loss. At Fountain, however, medication is only one part of the plan. Nutrition, physical activity, muscle preservation, sleep, metabolic health, and long-term weight maintenance are considered alongside the medication so the goal is improved health and body composition, not simply a lower number on the scale.

Semaglutide primarily acts on the GLP-1 receptor, while tirzepatide acts on both GLP-1 and GIP receptors. Both medications can reduce appetite and support meaningful weight loss, but they are different medications and patients may respond differently to each. The right choice depends on your medical history, goals, previous treatments, side effects, other medications, and how your body responds over time. Fountain does not assume that the medication associated with the most weight loss is automatically the best medication for every patient.

Some people notice changes in appetite relatively early, while others need more time before experiencing a meaningful effect. Weight change also varies substantially from person to person. Fountain generally takes a gradual approach to dose progression, with the goal of finding an effective and tolerable treatment rather than increasing the dose as quickly as possible. Early changes are less important than the trend in weight, body composition, appetite, metabolic health, and tolerability over time. Fountain’s internal GLP-1 protocol specifically uses slow, low-dose titration with ongoing clinical monitoring.

Common side effects include nausea, constipation, diarrhea, abdominal discomfort, reduced appetite, and sometimes vomiting. These symptoms are often most noticeable when beginning treatment or increasing the dose and may improve as the body adjusts. Persistent or severe symptoms should be discussed with your clinician. The objective is not to tolerate significant side effects in pursuit of faster weight loss. Dose progression can be adjusted based on your response, nutritional intake, symptoms, and overall health.

Weight loss can involve both body fat and lean tissue, which is why we do not evaluate progress using the scale alone. Adequate protein, resistance training, overall nutrition, recovery, and physical activity are important for preserving muscle and physical function during weight loss. Depending on your needs, Fountain can incorporate nutrition support, strength and fitness guidance, and body-composition assessment into your treatment plan. The goal is not simply weight loss. It is better body composition and metabolic health.

Tirzepatide treatment at Fountain is medically supervised rather than treated as a prescription-only weight-loss program. Fountain’s GLP-1 protocol includes gradual titration, regular clinical follow-up, baseline laboratory evaluation with follow-up testing when appropriate, and baseline and follow-up body-composition assessment. Patients also receive nutrition support, and treatment is continuously monitored for response and tolerability. Your care team can follow weight, body composition, nutrition, symptoms, side effects, metabolic markers, and other relevant health factors and adjust the plan as your body changes.